The FDA Breakthrough-Drug Designation — Four Years of Experience

Abstract

In 2012, Congress created the breakthrough-therapy designation to expedite the testing and approval by the FDA of medications with potential to provide substantial improvement over existing treatments. The authors review the first 4 years of experience with this program.